Pharmacokinetic analysis of amikacin twice and single daily dosage in immunocompromised pediatric patients

N. Krivoy*, S. Postovsky, R. Elhasid, M. Weyl Ben Arush

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Ten children received amikacin twice daily and 13 were treated using the single daily protocol. All had fever and neutropenia on admission, and received a total daily dose of 20 mg/kg when included in the study. Individual pharmacokinetic parameters were calculated using a one-compartment model for two blood amikacin samples. The mean (± SD) of elimination half-life (h), amikacin clearance (l/h/kg), volume of distribution (l/kg), peak concentration (μg/ml) and trough concentration (μg/ml) were: 2.51 (0.74) and 2.85 (0.32) h; 0.26 (0.16) and 0.115 (0.02) l/h/kg; 0.74 (0.44) and 0.47 (0.11) l/kg; 19.1 (12.3) and 42.6 (12.6) μg/ml; 0.85 (0.74) and 0.18 (0.24) μg/ml with twice and single daily dosage schedules, respectively. A single daily dose of amikacin had a significantly longer elimination half-life, lower clearance, higher peak concentration and lower trough concentration in comparison to the twice-daily schedule. The use of amikacin 20 mg/kg daily delivered in a single daily dose is recommended for immunocompromised pediatric patients with fever and neutropenia, in spite of the measured pharmacokinetic differences.

Original languageEnglish
Pages (from-to)396-398
Number of pages3
JournalInfection
Volume26
Issue number6
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Dive into the research topics of 'Pharmacokinetic analysis of amikacin twice and single daily dosage in immunocompromised pediatric patients'. Together they form a unique fingerprint.

Cite this